comparemela.com

Latest Breaking News On - C3ai inc - Page 1 : comparemela.com

Equities Research Analysts Updated EPS Estimates for December 7th (ACRX, AI, AMD, ANIX, AORT, ATH, AXGN, BDSX, BNED, BNOX)

Equities Research Analysts’ updated eps estimates for Thursday, December 7th: AcelRx Pharmaceuticals (NASDAQ:ACRX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $5.00 target price on the stock. C3.ai (NYSE:AI) had its hold rating reissued by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $27.00 […]

Stock Analysts Price Target Changes for June 1st (AAP, ABNB, ADM, AI, AJX, AMBA, APPH, AVY, BG, BIIB)

Stock Analysts’ price target changes for Thursday, June 1st: Advance Auto Parts (NYSE:AAP) had its target price cut by Barclays PLC from $129.00 to $69.00. Advance Auto Parts (NYSE:AAP) had its target price trimmed by Citigroup Inc. from $126.00 to $76.00. Advance Auto Parts (NYSE:AAP) had its target price reduced by Morgan Stanley from $130.00 […]

Research Analysts Upgrades for June 1st (AI, AYX, AZO, BLUE, BLX, BRLXF, CG, CHWY, CNVVY, CPHRF)

Research Analysts’ upgrades for Thursday, June 1st: C3.ai (NYSE:AI) was upgraded by analysts at Wedbush from a neutral rating to an outperform rating. The firm currently has $50.00 target price on the stock, up from their previous target price of $24.00. Alteryx (NYSE:AYX) was upgraded by analysts at Bank of America Co. from a neutral […]

Research Analysts Recent Ratings Updates for C3 ai (AI)

Several brokerages have updated their recommendations and price targets on shares of C3.ai (NYSE: AI) in the last few weeks: 6/9/2022 – C3.ai was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “C3.ai Inc. is an enterprise AI software provider for accelerating digital transformation. C3.ai […]

Research Analysts Updated EPS Estimates for June 9th (ADIL, AI, ALSMY, AMRX, AMSC, BPMC, CVAC, DBTX, DTIL, IMVT)

Research Analysts’ updated eps estimates for Thursday, June 9th: Adial Pharmaceuticals (NASDAQ:ADIL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.